US 12,404,319 B2
Methods and compositions for treating yellow fever
Yadunanda Kumar Budigi, Singapore (SG); Yok Hian Chionh, Singapore (SG); Debbie Ching Ping Lee, Singapore (SG); and Megan Earley McBee, Singapore (SG)
Assigned to WUXI BIOLOGICS IRELAND LIMITED, Dundalk (IE)
Filed by WUXI BIOLOGICS IRELAND LIMITED, Dundalk (IE)
Filed on Oct. 8, 2020, as Appl. No. 17/066,299.
Application 17/066,299 is a continuation of application No. PCT/US2019/027074, filed on Apr. 11, 2019.
Claims priority of provisional application 62/656,352, filed on Apr. 11, 2018.
Prior Publication US 2021/0139564 A1, May 13, 2021
Int. Cl. C07K 16/10 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01)
CPC C07K 16/1081 (2013.01) [A61P 31/14 (2018.01); A61K 2039/505 (2013.01); C07K 2317/41 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An antibody or antigen-binding portion thereof, wherein said antibody or antigen-binding portion thereof binds to an E-DII epitope of Yellow Fever Virus, and wherein the antibody or antigen-binding portion thereof comprises: a) the three CDRs of the heavy chain variable region (VH) as set forth in SEQ ID NO: 4; and the three CDRs of the light chain variable region (VL) as set forth in SEQ ID NO: 38.